| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | 0.058 | 0.07 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.07 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.08 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.053 | 0.08 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.056 | 0.08 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.067 | 0.08 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.08 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.088 | 0.08 |